CILK1

Serine/threonine-protein kinase ICK · Q9UPZ9 · CILK1 on Sugi Atlas →

2,809 patent compounds predicted against CILK1, 2,308 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Riviciclib (SCHEMBL290347)	1.00	2/20
Riviciclib (SCHEMBL663219)	1.00	2/20
Riviciclib (SCHEMBL663220)	1.00	2/20
Riviciclib (SCHEMBL290572)	0.98	2/20
Riviciclib (SCHEMBL291157)	0.98	2/20
Riviciclib (SCHEMBL665748)	0.98	2/20
Riviciclib (SCHEMBL665749)	0.98	2/20
Hydrochloric Acid (SCHEMBL2447940)	0.87	2/20
Hydrochloric Acid (SCHEMBL2447943)	0.87	2/20
Hydrochloric Acid (SCHEMBL2447947)	0.87	2/20
SCHEMBL2441179	0.85	2/20
SCHEMBL2441181	0.85	2/20
SCHEMBL2441187	0.85	2/20
SCHEMBL1179589	0.84	2/20
SCHEMBL1179591	0.84	2/20
SCHEMBL1180321	0.84	2/20
SCHEMBL1180324	0.84	2/20
SCHEMBL1180730	0.83	2/20
SCHEMBL1180734	0.83	2/20
Hydrochloric Acid (SCHEMBL1180100)	0.82	2/20

Clinical trials — most relevant to CILK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Efficacy and Safety of Ivarmacitinib Monotherapy in the Treatment of csDMARDs-IR Rheumatoid Arthritis	PHASE4	NOT_YET_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers	PHASE1/PHASE2	UNKNOWN
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer	PHASE2	RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC	PHASE1/PHASE2	COMPLETED
Cilostazol in Parkinson's Disease	PHASE2	NOT_YET_RECRUITING
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors	PHASE1	COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors	EARLY_PHASE1	UNKNOWN
Tumor Kinase Inhibitor Concentrations Measured by PET	nan	COMPLETED
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine)	nan	UNKNOWN
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Optimizing Cytokine-Induced Killer Cells in Glioblastoma Patients	nan	NOT_YET_RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CILK1 binder may also engage these)

Protein	Name	Similarity
Q9JKV2	—	1.000	Q9JKV2 →
Q62726	—	1.000	Q62726 →
P20793	—	0.999	P20793 →
MAK	Serine/threonine-protein kinase MAK	0.998	landscape →
CDKL5	Cyclin-dependent kinase-like 5	0.996	landscape →
Q3UTQ8	—	0.994	Q3UTQ8 →
Q04859	—	0.994	Q04859 →
B2GUY1	—	0.993	B2GUY1 →
Q0WPH8	—	0.992	Q0WPH8 →
P46200	—	0.992	P46200 →
Q8RX66	—	0.992	Q8RX66 →
Q14AX6	—	0.991	Q14AX6 →
Q3ULB5	—	0.991	Q3ULB5 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.991	landscape →
Q501Q9	—	0.991	Q501Q9 →
Q3MJK5	—	0.990	Q3MJK5 →
O97143	—	0.990	O97143 →
Q753D9	—	0.990	Q753D9 →
Q2QMH1	—	0.990	Q2QMH1 →
A7SNN5	—	0.990	A7SNN5 →
Q7ZVS3	—	0.990	Q7ZVS3 →
BMP2K	BMP-2-inducible protein kinase	0.990	landscape →
Q9TTK0	—	0.990	Q9TTK0 →
Q9URY1	—	0.990	Q9URY1 →
Q9CAU7	—	0.989	Q9CAU7 →
O43078	—	0.989	O43078 →
A0A1D9QMS2	—	0.989	A0A1D9QMS2 →
Q2LYK3	—	0.989	Q2LYK3 →
DYRK3	Dual specificity tyrosine-phosphorylation-regulated kinase 3	0.989	landscape →
Q63553	—	0.989	Q63553 →